Understand the source comparison
VIP Safety Profile: Research Model Comparison
The table below compares documented safety observations for VIP across species models, administration routes, and dose ranges reported in peer-reviewed literature. This data reflects aggregate findings from preclinical toxicity studies and early-phase clinical
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares documented safety observations for VIP across species models, administration routes, and dose ranges reported in peer-reviewed literature. This data reflects aggregate findings from preclinical toxicity studies and early-phase clinical trials published between 2010–2024.
- Rodent (mouse, rat)
- Subcutaneous
- 1–10 nmol/kg
- None at therapeutic doses; mild tachycardia at 10+ nmol/kg
- 5–10 minutes
- Excellent tolerability within standard research dose range; cardiovascular effects only at supra-therapeutic doses
- Intravenous bolus
- 5–50 nmol/kg
- Transient hypotension (8–12 mmHg) and tachycardia at doses >20 nmol/kg
- 10–15 minutes
- Rapid onset/offset; effects resolve without intervention; no cumulative toxicity
- Non-human primate
- Intravenous infusion
- 10–100 pmol/kg/min
- Mild hypotension and flushing at doses >50 pmol/kg/min
- During infusion + 5 min post
- Dose-dependent; well-tolerated at lower infusion rates; no organ toxicity
- Human (Phase I/II)
- 25–200 pmol/kg/min
- Transient hypotension (mean 8 mmHg drop), tachycardia, flushing
- 2–5 minutes post-infusion
- Self-limiting; no serious adverse events; cardiovascular effects managed via infusion rate adjustment
- Inhaled aerosol
- 25–100 mcg per dose
- Mild cough, throat irritation in <10% of subjects
- <5 minutes
- Localized effects only; no systemic cardiovascular changes; favorable for pulmonary applications
- Rodent (chronic dosing)
- Subcutaneous (daily × 28 days)
- 5 nmol/kg/day
- None detected; no histological changes on necropsy
- N/A
- No cumulative toxicity; repeated administration does not increase adverse event frequency
- Key findings: The VIP safety profile is most favorable at doses within the established therapeutic range (1–10 nmol/kg in rodents, 25–100 pmol/kg/min in humans). Adverse events are transient, dose-dependent, and resolve without medical intervention. No delayed toxicity, organ damage, or hypersensitivity reactions have been documented across species models or dosing schedules.